MaTAR25 lncRNA regulates the Tensin1 gene to impact breast cancer progression

Chang, K. C., Diermeier, S. D., Yu, A. T., Brine, L. D., Russo, S., Bhatia, S., Alsudani, H., Kostroff, K., Bhuiya, T., Brogi, E., Pappin, D. J., Bennett, C. F., Rigo, F., Spector, D. L. (December 2020) MaTAR25 lncRNA regulates the Tensin1 gene to impact breast cancer progression. Nat Commun, 11 (1). p. 6438. ISSN 2041-1723

URL: https://pubmed.ncbi.nlm.nih.gov/33353933/
DOI: 10.1038/s41467-020-20207-y

Abstract

Misregulation of long non-coding RNA (lncRNA) genes has been linked to a wide variety of cancer types. Here we report on Mammary Tumor Associated RNA 25 (MaTAR25), a nuclear enriched and chromatin associated lncRNA that plays a role in mammary tumor cell proliferation, migration, and invasion, both in vitro and in vivo. MaTAR25 functions by interacting with purine rich element binding protein B (PURB), and associating with a major downstream target gene Tensin1 (Tns1) to regulate its expression in trans. The Tns1 protein product is a critical component of focal adhesions linking signaling between the extracellular matrix and the actin cytoskeleton. Knockout of MaTAR25 results in down-regulation of Tns1 leading to a reorganization of the actin cytoskeleton, and a reduction of focal adhesions and microvilli. We identify LINC01271 as the human ortholog of MaTAR25, and importantly, increased expression of LINC01271 is associated with poor patient prognosis and metastasis. Our findings demonstrate that LINC01271 represents a potential therapeutic target to alter breast cancer progression.

Item Type: Paper
CSHL Authors:
Communities: CSHL labs > Pappin lab
CSHL labs > Spector lab
Depositing User: Matthew Dunn
Date: 22 December 2020
Date Deposited: 19 Apr 2021 19:02
Last Modified: 19 Apr 2021 19:02
Related URLs:
URI: https://repository.cshl.edu/id/eprint/39849

Actions (login required)

Administrator's edit/view item Administrator's edit/view item
CSHL HomeAbout CSHLResearchEducationNews & FeaturesCampus & Public EventsCareersGiving